150 related articles for article (PubMed ID: 2149501)
1. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
2. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
4. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
5. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
6. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
7. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
8. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.
Santen RJ
Breast Cancer Res Treat; 1981; 1(3):183-202. PubMed ID: 6293627
[TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
10. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
12. Low-dose aminoglutethimide in treatment of advanced breast cancer.
Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
[TBL] [Abstract][Full Text] [Related]
13. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
15. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
[TBL] [Abstract][Full Text] [Related]
16. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G; Bisagni G; Ceci G; Bacchi M; Boni C; Brugia M; Carpi A; Di Costanzo F; Franciosi V; Gori S
J Clin Oncol; 1992 Jun; 10(6):984-9. PubMed ID: 1588379
[TBL] [Abstract][Full Text] [Related]
17. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer.
Mercer PM; Ebbs SR; Fraser SC; Coltart RS; Bates T
Eur J Surg Oncol; 1993 Jun; 19(3):254-8. PubMed ID: 8314383
[TBL] [Abstract][Full Text] [Related]
18. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
[TBL] [Abstract][Full Text] [Related]
19. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
20. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
